1
00:00:02,200 --> 00:00:07,765
SS-31 takes peptide science inside the
mitochondrion,

2
00:00:07,914 --> 00:00:11,632
where a membrane's architecture helps cells produce
energy.

3
00:00:11,799 --> 00:00:18,433
Also called elamipretide, this four-amino-acid
molecule belongs to the Szeto-Schiller family.

4
00:00:18,575 --> 00:00:24,690
Hazel Szeto at Cornell in New York and Peter
Schiller in Montreal helped develop the peptides.

5
00:00:24,911 --> 00:00:30,016
A landmark paper appeared in 2004: more than twenty
years of published research.

6
00:00:30,234 --> 00:00:35,471
Its partner is cardiolipin, a lipid in the inner
mitochondrial membrane.

7
00:00:35,609 --> 00:00:41,238
This membrane folds into cristae, supporting
electron transport and production of ATP,

8
00:00:41,415 --> 00:00:43,095
the cell's energy currency.

9
00:00:43,242 --> 00:00:48,776
Laboratory studies found that SS-31 interacts with
cardiolipin and supports

10
00:00:48,776 --> 00:00:51,019
mitochondrial energy processes.

11
00:00:51,220 --> 00:00:56,740
A small randomized study in older adults reported
improved muscle mitochondrial energy

12
00:00:56,740 --> 00:00:59,208
production after one infusion.

13
00:00:59,438 --> 00:01:03,166
This did not establish longer life or lasting
performance benefits.

14
00:01:03,397 --> 00:01:08,987
In September 2025, the FDA granted accelerated
approval to Forzinity,

15
00:01:09,192 --> 00:01:14,566
an elamipretide medicine, to improve muscle
strength in adults and children with

16
00:01:14,566 --> 00:01:17,843
Barth syndrome weighing at least thirty kilograms.

17
00:01:18,048 --> 00:01:21,889
This rare genetic condition affects mitochondrial
function.

18
00:01:22,180 --> 00:01:27,167
Approval drew on knee-extensor strength
improvements during an open-label extension.

19
00:01:27,410 --> 00:01:33,298
The randomized trial did not show superiority on
its walking and fatigue primary endpoints.

20
00:01:33,538 --> 00:01:35,699
A confirmatory trial is required.

21
00:01:35,869 --> 00:01:41,163
Risks include injection-site reactions and serious
allergic reactions.

22
00:01:41,351 --> 00:01:46,973
This specific approval does not cover general
anti-aging use or every product sold

23
00:01:46,973 --> 00:01:48,550
as SS-31.

24
00:01:48,785 --> 00:01:53,700
From molecular design to a rare-disease medicine,
its story shows why

25
00:01:53,967 --> 00:01:55,943
mitochondrial membranes matter.

26
00:01:56,283 --> 00:01:58,004
World Peptide Foundation.

27
00:01:58,236 --> 00:01:59,701
Peptides in 2.

28
00:01:59,858 --> 00:02:01,558
Every experience matters.
